Ex-Pfizer CEO Ian Read in 2017 (Kristoffer Tripplaar/Sipa via AP Images)
October 9, 2024 11:28 PM EDTUpdated 07:42 AM
People
Pharma

For­mer Pfiz­er CEO and CFO flip on ac­tivist and say they now sup­port com­pa­ny

Drew Armstrong

Executive Editor

Max Bayer

Pharma Reporter

In a late-night re­ver­sal, Pfiz­er’s for­mer CEO and CFO is­sued a state­ment say­ing they now sup­port the com­pa­ny’s ex­ist­ing man­age­ment over ac­tivist in­vestor Star­board Val­ue …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

A service from the Financial Times